Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease

OBJECTIVES: Interleukin-23 (IL-23) has emerged as a new therapeutic target for the treatment of inflammatory bowel disease (IBD). As biomarkers of disease state and treatment efficacy are becoming increasingly important in drug development, we sought to identify efficacy biomarkers for anti-IL-23 th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cayatte, Corinne, Joyce-Shaikh, Barbara, Vega, Felix, Boniface, Katia, Grein, Jeffrey, Murphy, Erin, Blumenschein, Wendy M, Chen, Smiley, Malinao, Maria-Christina, Basham, Beth, Pierce, Robert H, Bowman, Edward P, McKenzie, Brent S, Elson, Charles O, Faubion, William A, Malefyt, Rene de Waal, Kastelein, Robert A, Cua, Daniel, McClanahan, Terrill K, Beaumont, Maribel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365674/
https://www.ncbi.nlm.nih.gov/pubmed/23238132
http://dx.doi.org/10.1038/ctg.2012.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365674/
https://www.ncbi.nlm.nih.gov/pubmed/23238132
http://dx.doi.org/10.1038/ctg.2012.2

Ejemplares similares